The hub plans to build on the existing partnership with UH and Baylor, as well as other clinical and research groups within the Texas Medical Center. Photo via Getty Images

The University of Houston and Baylor College of Medicine have been awarded a sizable grant to create a regional research hub.

The National Center for Advancing Translational Research awarded the $44.2 million Clinical and Translational Science Award Program grant to the two schools, which will work to create a regional hub called the Consortium for Translational and Precision Health. CTPH will “serve as a support for infrastructure, services, community engagement and workforce development to advance research and drive innovation in clinical translational science,” per a UH news release.

The hub plans to build on the existing partnership with UH and Baylor, as well as other clinical and research groups within the Texas Medical Center. CTPH aims to connect regional investigators with community healthcare organizations and government agencies that contribute to clinical research, healthcare, and policy. The new hub plans to provide funding for projects in pilot, and support ongoing research to help “accelerate the pace of research from discovery to population level impact,” according to the release. Over 60 leading medical institutions receive CTSA Program funding.

“Research is the engine empowering health care’s life-changing advancements,” UH President Renu Khator says in a news release. “This innovative hub will be a catalyst for groundbreaking discoveries and treatments that improve people’s quality of life. That’s what drives us at UH and we’re ecstatic to cofound a regional hub for change alongside Baylor.”

Leading the program will be Dr. Christopher Amos, professor and director of the Institute for Clinical and Translational Research (ICTR) at BCM; Dr. Fasiha Kanwal, professor of medicine and chief of the section of gastroenterology and hepatology at BCM; and Dr. Bettina M. Beech, clinical professor of population health and the chief population health officer at UH.

The CTPH will also work with Tilman J. Fertitta Family College of Medicine, Andy & Barbara Gessner College of Nursing, College of Pharmacy, College of Optometry, C. T. Bauer College of Business, Cullen College of Engineering, College of Natural Sciences and Mathematics, College of Education, College of Liberal Arts and Social Sciences, and the Honors College — all UH colleges.

“We are deeply committed to advancing innovation in clinical and translational science, and this award is a significant step forward in our mission to improve population health outcomes,” Beech says in a news release. “This is a testament to the unwavering dedication and collaborative spirit of everyone involved. It truly was a team effort.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

German biotech co. to relocate to Houston thanks to $4.75M CPRIT grant

money moves

Armed with a $4.75 million grant from the Cancer Prevention and Research Institute of Texas, a German biotech company will relocate to Houston to work on developing a cancer medicine that fights solid tumors.

Eisbach Bio is conducting a clinical trial of its EIS-12656 therapy at Houston’s MD Anderson Cancer Center. In September, the company announced its first patient had undergone EIS-12656 treatment. EIS-12656 works by suppressing cancer-related genome reorganization generated by DNA.

The funding from the cancer institute will support the second phase of the EIS-12656 trial, focusing on homologous recombination deficiency (HRD) tumors.

“HRD occurs when a cell loses its ability to repair double-strand DNA breaks, leading to genomic alterations and instability that can contribute to cancerous tumor growth,” says the institute.

HRD is a biomarker found in most advanced stages of ovarian cancer, according to Medical News Today. DNA constantly undergoes damage and repairs. One of the repair routes is the

homologous recombination repair (HRR) system.

Genetic mutations, specifically those in the BCRA1 and BCRA1 genes, cause an estimated 10 percent of cases of ovarian cancer, says Medical News Today.

The Cancer Prevention and Research Institute of Texas (CPRIT) says the Eisbach Bio funding will bolster the company’s “transformative approach to HRD tumor therapy, positioning Texas as a hub for innovative cancer treatments while expanding clinical options for HRD patients.”

The cancer institute also handed out grants to recruit several researchers to Houston:

  • $2 million to recruit Norihiro Goto from the Massachusetts Institute of Technology to MD Anderson.
  • $2 million to recruit Xufeng Chen from New York University to MD Anderson.
  • $2 million to recruit Xiangdong Lv from MD Anderson to the University of Texas Health Science Center at Houston.

In addition, the institute awarded:

  • $9,513,569 to Houston-based Marker Therapeutics for a first-phase study to develop T cell-based immunotherapy for treatment of metastatic pancreatic cancer.
  • $2,499,990 to Lewis Foxhall of MD Anderson for a colorectal cancer screening program.
  • $1,499,997 to Abigail Zamorano of the University of Texas Health Science Center at Houston for a cervical cancer screening program.
  • $1,497,342 to Jennifer Minnix of MD Anderson for a lung cancer screening program in Northeast Texas.
  • $449,929 to Roger Zoorob of the Baylor College of Medicine for early prevention of lung cancer.

On November 20, the Cancer Prevention and Research Institute granted funding of $89 million to an array of people and organizations involved in cancer prevention and research.

West Coast innovation organization unveils new location in Houston suburb to boost Texas tech ecosystem

plugging in

Leading innovation platform Plug and Play announced the opening of its new flagship Houston-area location in Sugar Land, which is its fourth location in Texas.

Plug and Play has accelerated over 2,700 startups globally last year with corporate partners that include Dell Technologies, Daikin, Microsoft, LG Chem, Shell, and Mercedes. The company’s portfolio includes PayPal, Dropbox, LendingClub, and Course Hero, with 8 percent of the portfolio valued at over $100 million.

The deal, which facilitated by the Sugar Land Office of Economic Development and Tourism, will bring a new office for the organization to Sugar Land Town Square with leasing and hiring between December and January. The official launch is slated for the first quarter of 2025, and will feature 15 startups announced on Selection Day.

"By expanding to Sugar Land, we’re creating a space where startups can access resources, build partnerships, and scale rapidly,” VP Growth Strategy at Plug and Play Sherif Saadawi says in a news release. “This location will help fuel Texas' innovation ecosystem, providing entrepreneurs with the tools and networks they need to drive real-world impact and contribute to the state’s technological and economic growth."

Plug and Play plans to hire four full-time equivalent employees and accelerate two startup batches per year. The focus will be on “smart cities,” which include energy, health, transportation, and mobility sectors. One Sugar Land City representative will serve as a board member.

“We are excited to welcome Plug and Play to Sugar Land,” Mayor of Sugar Land Joe Zimmerma adds. “This investment will help us connect with corporate contacts and experts in startups and businesses that would take us many years to reach on our own. It allows us to create a presence, attract investments and jobs to the city, and hopefully become a base of operations for some of these high-growth companies.”

The organization originally entered the Houston market in 2019 and now has locations in Bryan/College Station, Frisco, and Cedar Park in Texas.